HIV vaccine - Peptimmune

Drug Profile

HIV vaccine - Peptimmune

Latest Information Update: 03 Aug 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Developer Nonindustrial source; Peptimmune
  • Class AIDS vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 03 Aug 2004 Discontinued - Preclinical for HIV-1 infections in USA (unspecified route)
  • 13 Jul 2001 No-Development-Reported for HIV-1 infections in USA (Unknown route)
  • 05 Dec 1997 Preclinical development for HIV-1 infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top